These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32966574)

  • 1. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.
    Khanna S; Pardi DS; Jones C; Shannon WD; Gonzalez C; Blount K
    Clin Infect Dis; 2021 Oct; 73(7):e1613-e1620. PubMed ID: 32966574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
    Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
    BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
    Chopra T
    Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiota restoration therapies for recurrent
    DuPont HL; DuPont AW; Tillotson GS
    Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
    Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
    Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
    Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
    Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection.
    Hunt A; Drwiega E; Wang Y; Danziger L
    Am J Health Syst Pharm; 2024 Jul; 81(15):e402-e411. PubMed ID: 38470061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of fecal microbiota, live-jslm (REBYOTA
    Lee C; Louie T; Bancke L; Guthmueller B; Harvey A; Feuerstadt P; Khanna S; Orenstein R; Dubberke ER
    Therap Adv Gastroenterol; 2023; 16():17562848231174277. PubMed ID: 37333464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SER-109 (VOWST
    Blair HA
    Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiome therapeutics for the treatment of recurrent
    Bloom PP; Young VB
    Expert Opin Biol Ther; 2023 Jan; 23(1):89-101. PubMed ID: 36536532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
    Sims MD; Khanna S; Feuerstadt P; Louie TJ; Kelly CR; Huang ES; Hohmann EL; Wang EEL; Oneto C; Cohen SH; Berenson CS; Korman L; Lee C; Lashner B; Kraft CS; Ramesh M; Silverman M; Pardi DS; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L;
    JAMA Netw Open; 2023 Feb; 6(2):e2255758. PubMed ID: 36780159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
    McGovern BH; Ford CB; Henn MR; Pardi DS; Khanna S; Hohmann EL; O'Brien EJ; Desjardins CA; Bernardo P; Wortman JR; Lombardo MJ; Litcofsky KD; Winkler JA; McChalicher CWJ; Li SS; Tomlinson AD; Nandakumar M; Cook DN; Pomerantz RJ; Auninš JG; Trucksis M
    Clin Infect Dis; 2021 Jun; 72(12):2132-2140. PubMed ID: 32255488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
    Berry P; Khanna S
    BioDrugs; 2023 Nov; 37(6):757-773. PubMed ID: 37493938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
    Berenson CS; Lashner B; Korman LY; Hohmann E; Deshpande A; Louie TJ; Sims M; Pardi D; Kraft CS; Wang EEL; Cohen SH; Feuerstadt P; Oneto C; Misra B; Pullman J; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L; Lee CH
    Clin Infect Dis; 2023 Nov; 77(11):1504-1510. PubMed ID: 37539715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
    Feuerstadt P; Crawford CV; Tan X; Pokhilko V; Bancke L; Ng S; Guthmueller B; Bidell MR; Tillotson G; Johnson S; Skinner AM
    J Clin Gastroenterol; 2024 Sep; 58(8):818-824. PubMed ID: 38019088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
    Khanna S
    J Intern Med; 2021 Aug; 290(2):294-309. PubMed ID: 33856727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal microbiota transplantation for treatment of patients with recurrent
    Voth E; Khanna S
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):669-676. PubMed ID: 32266848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
    Orenstein R
    Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.